Ameriprise
MLYS icon

Ameriprise’s Mineralys Therapeutics MLYS Stock Holding History

Ameriprise’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$772K Sell
28,630
-192,675
-87% -$5.29M ﹤0.01% 3515
2026
Q1 		$6M Buy
221,305
+175,059
+379% +$5.13M ﹤0.01% 2316
2025
Q4 		$1.68M Sell
46,246
-50,901
-52% -$2.04M ﹤0.01% 3090
2025
Q3 		$3.68M Buy
97,147
+46,290
+91% +$1M ﹤0.01% 2643
2025
Q2 		$688K Buy
+50,857
New +$737K ﹤0.01% 3414

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ameriprise's MLYS Position: Q2 2026 in Review

Ameriprise reduced its Mineralys Therapeutics (MLYS) stake by 87% in Q2 2026, selling an estimated $5.29M and leaving 28,630 shares worth $772K. The position accounts for ﹤0.01% of the portfolio, ranked #3515.

Ameriprise first reported a position in MLYS in Q2 2025 and has held it in 5 quarters since. The position peaked at $6M in Q1 2026. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Ameriprise held 28,630 shares of Mineralys Therapeutics worth $772K as of Q2 2026.
  • Ameriprise sold 192,675 Mineralys Therapeutics shares in Q2 2026, an estimated $5.29M.
  • Mineralys Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3515 holding.
  • Ameriprise first reported a position in Mineralys Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Ameriprise's Mineralys Therapeutics position peaked at $6M in Q1 2026.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.